UPDATE: An attorney representing Forcyte Biotechnologies updated the securities filing on Jan. 15, after realizing the earlier filing was made in error, said company founder Ivan Pushkarsky. The company amended the filing to say it had sold $160,000 in securities out of a $2 million securities offering. The biomedical firm is now being incubated at Los Angeles Biomedical Research Institute in Torrance.

Forcyte Biotechnologies Inc., a Brentwood-based biotechnology startup with roots at UCLA, has raised $1 million in investor funding, according to a securities filing.

The company sold the securities to three investors during a $2 million offering, according to the Jan. 10 filing with the U.S. Securities and Exchange Commission.

Forcyte Biotechnologies develops single-cell microtechnology known as FLECS to help develop a range of drugs to treat migraine headaches to cardiovascular disease.

The approach to discover drugs that modulates cell force generation sprung from tech developed at a laboratory in the Department of Bioengineering at UCLA.

The firm was founded in 2017 by UCLA bioengineering professors Ivan Pushkarsky and Dino Di Carlo, as well as Robert Damoiseaux, a UCLA professor of molecular and medical pharmacology.

Health business reporter Dana Bartholomew can be reached at [email protected]. Follow him on Twitter @_DanaBart.